Metropolis Healthcare Limited has informed the Exchange regarding a press release dated May 13, 2026, titled " Metropolis Healthcare reports strong Q4FY26 performance; EBITDA up 71% YoY and PAT rises 75% YoY. ".
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Metropolis Healthcare reported strong Q4FY26 results with revenue of INR 425 Cr, up 23% YoY, driven by 11% patient volume growth and 14% test volume growth. EBITDA surged 71% to INR 108 Cr with margin expanding to 25.4% (vs 18.5% in Q4FY25), reflecting operational efficiencies and favourable revenue mix. PAT grew 75% to INR 51 Cr. B2C revenues rose 20% and B2B revenues jumped 28% YoY. The company crossed 5,000+ centres milestone. The Board approved a dividend of INR 1 per share. For FY26, group revenue was INR 1,646 Cr (24% YoY) and PAT was INR 191 Cr (31% YoY).
Strong margin expansion and profitability growth indicate operational leverage working well; the stock appears well-positioned with healthy volume growth, mix improvement and no price hikes - a positive signal for shareholders.